Skip to content

Author

Masoume Aliabadi

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Co-administration of empagliflozin and curcumin attenuates the development of MASLD by modulating lipid metabolism and adipose tissue browning in HFD-fed C57BL/6J mice.

The increasing global incidence of metabolic dysfunction-associated steatotic liver disease (MASLD) highlights the need for effective treatment strategies. This study investigated the combined effects of empagliflozin (EMPA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and curcumin (Cur), a natural polyphenol,...

Masoume Aliabadi, A. Soleimani, G. Taheripak et al. · 0 citations
Oct 2026

Combination of Empagliflozin and Resveratrol Mitigates Hepatic Steatosis via Attenuation of Inflammation and Promotion of Adipose Tissue Browning in High‐Fat Diet‐Fed C57BL/6J Mice

The combined effects of empagliflozin and resveratrol treatment on obesity‐associated MASLD in a high‐fat diet (HFD)‐fed mouse model reduced body weight gain and improved glucose tolerance more effectively than monotherapies.

A. Soleimani, Masoume Aliabadi, Jamal Amri et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.